# Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients

> **NCT00503516** · PHASE2,PHASE3 · TERMINATED · sponsor: **Rottapharm Spain** · enrollment: 39 (actual)

## Conditions studied

- Dementia

## Interventions

- **DRUG:** Megestrol acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00503516
- **Lead sponsor:** Rottapharm Spain
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-12
- **Final completion:** 2010-02
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Difficulties to recruit the patients following the inclusion criteria
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503516, "Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00503516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*